🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

George Soros’s ETRA Holdings & Trades

First Buy
Q3 2026
Duration Held
1 Quarters
Largest Add
Q3 2026
+75,000 Shares
Current Position
75,000 Shares
$843,750 Value

George Soros's ETRA Position Overview

George Soros (via Soros Fund Management LLC) currently holds 75,000 shares of Electra Therapeutics, Inc. (ETRA) worth $843,750, representing 0.01% of the portfolio. First purchased in 2026-Q3, this recently established position has been held for 1 quarters.

Based on recent 13F filings, George Soros has initiated a new position in ETRA, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

George Soros's Electra Therapeutics (ETRA) Holding Value Over Time

Track share changes against reported price movement

Quarterly Electra Therapeutics (ETRA) Trades by George Soros

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +75,000 New Buy 75,000 $11.25

George Soros's Electra Therapeutics Investment FAQs

George Soros first purchased Electra Therapeutics, Inc. (ETRA) in Q3 2026, acquiring 75,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

George Soros has held Electra Therapeutics, Inc. (ETRA) for 1 quarters since Q3 2026.

George Soros's largest addition to Electra Therapeutics, Inc. (ETRA) was in Q3 2026, adding 75,000 shares worth $843,750.

According to the latest 13F filing for Q3 2026, George Soros's firm, Soros Fund Management LLC, owns 75,000 shares of Electra Therapeutics, Inc. (ETRA), valued at approximately $843,750.

As of the Q3 2026 filing, Electra Therapeutics, Inc. (ETRA) represents approximately 0.01% of George Soros's publicly disclosed stock portfolio, making it one of their key holdings.

George Soros's peak holding in Electra Therapeutics, Inc. (ETRA) was 75,000 shares, as reported at the end of Q3 2026.